This week is RSV Awareness Week and at hVIVO, we’re proud to be at the forefront of innovation in RSV research and development. Respiratory Syncytial Virus (RSV) continues to pose a significant global health challenge, particularly for infants, older adults, and immunocompromised individuals. At hVIVO, we provide comprehensive, end-to-end support for the development and evaluation of RSV vaccines and antiviral therapeutics through our world-leading controlled human infection models and specialist laboratory services.
Let’s work together to advance RSV science and protect vulnerable populations.
Learn more about our dedicated RSV human challenge trial services by clicking on the link below or reach out directly on bd@hvivo.com:
hvivo.com/human-challenge-mo…
#HVO #RSVWeek #RSV #ClinicalTrials #Vaccines #Antivirals #hLAB